Grünenthal On Hunt For Asia Partner As Pain Killer Hits Phase III Endpoints

Grünenthal’s novel pain killer has succeeded in a Phase III trial in cancer pain and now the company wants to find a partner for Asian markets, to complement its deal last year with Depomed for North America.